Atara Biotherapeutics Provides Regulatory And Business Updates On Tabelecleucel (Tab-Cel)
ReutersJul 14, 2025 12:13 PM
July 14 (Reuters) - Atara Biotherapeutics Inc ATRA.O:
ATARA BIOTHERAPEUTICS PROVIDES REGULATORY AND BUSINESS UPDATES ON TABELECLEUCEL (TAB-CEL®)
ATARA BIOTHERAPEUTICS INC - BLA APPROVAL TO TRIGGER $40 MILLION MILESTONE PAYMENT
ATARA BIOTHERAPEUTICS INC - PROJECTS $22M CASH AND INVESTMENTS AS OF JUNE 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
Is Now the Time to Invest in U.S. Stocks Amid Renewed Tariff Uncertainty?
TradingKey - On July 7, President Donald Trump posted a letter addressed to 14 world leaders outlining his updated tariff strategy.TradingKey
6 hours ago
Goldman Sachs 2025 Second Quarter Earnings Comments
TradingKey - Goldman Sachs management is optimistic about future growth, expecting investment banking to continue benefiting from robust M&A activity.TradingKey
10 hours ago
ASML Q2 FY2025 Earnings Review: Strong Growth and High-NA EUV Breakthrough Shadowed by 2026 Uncertainty
ASML Holding N.V. (NASDAQ: ASML) released its Q2 FY2025 earnings on July 16, 2025, exceeding market expectations with robust net sales and net bookings, though the stock fell around 10% due to cautious guidance for 2026 amid geopolitical uncertainties.TradingKey
Mon, Jul 14
TSMC's Q1 2025 Earning: Technological leadership and AI demand drive continued growth in performance
For investors, TSMC's current valuation has not yet fully reflected its growth potential in the AI chip market. It is recommended to pay attention to its progress in 2nm process mass production and CoWoS capacity expansion.TradingKey
Thu, Apr 17
TSMC 2025 Q1 Outlook: AI-Driven Growth and Supply Chain Breakthrough Amid Tariff Pressures
As the world's leading semiconductor foundry, TSMC's Q1 2025 revenue reached NT$839.254 billion, a year-on-year increase of 41.6%, exceeding market expectations and in line with the company's guidance of NT$820 billion to NT$846.24 billion.TradingKey
Tue, Apr 15
Tradingkey
